occurs with FT) but instead are the progeny of cells that are undergoing S phase at the time of labeling. After i.p. injection into pregnant mice, BrdU labeling is detected within 30 min, and dividing cells incorporate BrdU during a time window of~2-6 h 2,4 . To reveal BrdU labeling, tissue fixation and an aggressive DNA denaturation protocol are required 3 , such that BrdU birth-dating cannot be combined with applications in which live cells must be isolated or analyzed, including live imaging, electrophysiology and transcriptomics. Other thymidine analogs, such as 5-ethynyl-2-deoxyuridine (EdU), 5-chloro-2′-deoxyuridine and 5-iodo-2′-deoxyuridine, exist and can be used for combinatorial labeling of cells born at different times, but such procedures have the same limitations as BrdU labeling 5 . Finally, BrdU is also incorporated during nucleotide replacement during DNA repair 6 (which occurs during early neuron differentiation 7, 8 ) such that it is not an entirely specific marker of S-phase. The results of BrdU experiments should thus be examined with caution depending on context.
Another birth-dating technique that partially overcomes the limitations of BrdU is viral labeling. This approach relies on the use of a replication-deficient virus (typically a retrovirus) expressing a reporter protein 9 . The virus is injected into the cerebral ventricles of developing embryos, from where it infects cells that are located at the ventricular border. Upon infection, the virus integrates into the genome and initiates expression of a reporter protein. Although this approach is compatible with in and ex vivo applications, such as live imaging, and infection is limited to a specific cohort of cells (even allowing clonal analysis when very low titers of viruses are used 10 ), a major limitation is that it takes a considerable amount of time until the fluorescent reporter is expressed (usually about a day or more in the mouse 11 ), such that the precise time of birth of the labeled neurons is difficult to determine without using additional approaches (such as BrdU birth-dating). This limitation makes it difficult to use viral labeling to analyze cells immediately after their birth 9, 12 . A third commonly used approach for labeling newborn cells in the developing brain is in utero electroporation. In this procedure, a plasmid coding for a reporter protein is injected into the ventricle, and electrical pulses are applied to enable the entry of the plasmid into cells. Plasmid transfer is most efficient in M-phase cells, but also affects S-phase cells and is not restricted to the ventricular border 13, 14 (see, in particular, Supplementary Fig. 1 in ref. 14 , in which a BrdU-labeled plasmid was used to identify cells exposed to the plasmid immediately after electroporation, revealing that all VZ and SVZ cells are exposed). Thus, a broad range of unsynchronized progenitors are labeled, which makes analysis of the progeny complex, in terms of developmental trajectories and lineage relationships. Another limitation of in utero electroporation is that detection of labeled cells is possible only after expression of the reporter protein (typically~10 h in the mouse 14 ), making it difficult to study events occurring upon or immediately after cell division. progenitors takes place as the cell soma is in contact with the ventricular space, whereas all subsequent stages of the cell cycle occur further away from the ventricle. This process is termed interkinetic migration. Injection of FlashTag solution (FT) into the ventricle results in the specific labeling of M-phase cells because of their anatomical location at mitosis. b, Twenty minutes after labeling, strong fluorescence (green (FT); blue (DAPI)) is observed along the entire ventricular wall. Scale bar, 100 μm. c, FT (green) labels mitotic cells at the ventricular border, as identified by the expression of the mitosis-specific marker phospho-histone H3 (PH3, red) in labeled cells. Labeling is restricted to a period of 1-2 h, and cells born 3 h after labeling (PH3 + ) are FT -. Scale bar, 30 μm. E, embryonic day; LV, lateral ventricle. a,c adapted with permission from ref. 7 , American Association for the Advancement of Science. For all experiments involving animals, appropriate institutional regulatory board permission was obtained.
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To circumvent the limitations of the birth-dating techniques described above, we recently developed FT to birth-date, track and isolate isochronic cohorts of VZ-born cells in the developing CNS 7 . In this approach, cells are labeled with carboxyfluorescein diacetate succinimidyl ester (CFDA-SE), which fluoresces only after it is taken up by cells. This technique takes advantage of the fact that VZ progenitors divide exclusively at the ventricular wall, where they can be specifically labeled, and allows labeling of a spatially defined cohort (cells in the VZ across the CNS) of cell-cycle phase-locked cells (M phase) with a high temporal resolution ( Fig. 1) : an intracellular fluorescence signal is detected within 20 min (Fig. 1b) . Furthermore, at least in the neocortex, labeling is restricted to the 1-2 h (i.e., one to two rounds of mitosis) that follow injection (Fig. 1c) . The fluorescence signal can be detected without immunohistochemistry, allowing FT to be used for ex vivo (and, in principle, in vivo) live imaging and electrophysiology, as well as to isolate progenitors and neurons for cell culture or bulk/ single-cell RNA sequencing.
FlashTag principle and direct comparison with BrdU and in utero electroporation
To perform FlashTag, CFSE or a related ester-derived fluorophore (Reagents), is injected into the ventricular cavities, resulting in the labeling of mitotic cells at the ventricular border, whose somata are in direct contact with the cerebrospinal fluid. CFSE is colorless when it is extracellular and becomes fluorescent only after being enzymatically processed inside the cell (see Box 1 for details), such that 20 min after injection, high intracellular fluorescence is observed along the entire ventricular wall (Fig. 1b) . Although weak fluorescence can be observed in cells further away from the ventricular border (most probably due to diffusion or uptake through end-feet extending to the ventricular wall), only cells whose somata are in direct contact with the ventricular space show high levels of fluorescence. Weak labeling through nonmitotic uptake of CFSE can be 16, 17 . It is a nonfluorescent molecule that is highly membrane-permeant because of its acetate groups. Upon cell entry, intracellular esterases cleave the acetate groups, resulting in a fluorescent and membrane nonpermeant carboxyfluorescein succinimidyl ester (CFSE) that is trapped inside the cell. The succinimidyl chains of CFSE covalently bind to the amino groups of intracellular proteins, leading to long-lived labeling of the cell. At each cell division, CFSE is divided between the progeny, resulting in dilution of the signal 15 .
eliminated by setting a maximum intensity threshold during FACS or histological analysis (see below).
Once injected into the ventricle, FT labeling occurs for a time window of 1-2 h: while 1 h after labeling, all mitotic progenitors at the ventricular border (identified by expression of the mitosis-specific marker phospho-histone H3 (PH3)) are labeled with FT, 2 h after labeling, most new mitotic cells are not FT + and 3 h after injection, none of the PH3 + cells at the ventricular border are FT + ; in addition, at this point, FT + cells will have moved away from the ventricular border (Fig. 1c) . Thus, the specific labeling of mitotic progenitors is the consequence of the dynamic phase-cyclerelated anatomical position of the cell somata together with the rapid clearance of CFSE from the cerebrospinal fluid.
Once inside the cell, FT is diluted at each cell division, such that FT intensity can in principle be used to determine the number of cell divisions that have occurred between labeling and collection. This principle has long been applied in the hematopoietic system 15 and can, to a certain extent, be applied to the CNS to distinguish neurons born directly from the VZ from those born indirectly via intermediate progenitors in the SVZ 7 . Labeled progenitors progressively dilute their initial label content upon successive divisions. In T lymphocytes, up to six CFSE dilution peaks can be detected by FACS 15 , and a similar number is estimated for FT − -labeled cells in the neocortex. After FT at E12.5, labeling progressively dilutes out from layer 6 (L6) neurons to L4 neurons (only a few very weakly labeled cells are found in L2/3). This can be estimated to correspond to four to five rounds of cell division of the initially labeled cells, as single E12.5 progenitors are thought to divide six to seven times during corticogenesis 16 . In the neocortex, we used chronic i.p. BrdU perfusion from the time of FT injection to label all cells that entered S phase at any time point after FT labeling (Fig. 2a,b) . When examined at postnatal day 7 (P7), only 10% of the brightest FT + cells were also BrdU + , indicating that the brightest FT + cells are overwhelmingly born from VZ progenitors at the time of labeling (Fig. 2c) . Given that region-and stage-specific properties exist across germinal zones, this calibration should be performed on a case-by-case basis.
To directly compare FT birth-dating with BrdU birth-dating, we pulse-injected BrdU at the time of FT labeling. Although a broad set of S-phase progenitors in the cortical VZ and SVZ are labeled by BrdU, FT specifically labels M-phase cells at the ventricular border, such that these two markers label essentially mutually exclusive populations of cells (Fig. 3a) . When examined at P7, daughter FT + neurons are found in a thin neocortical sublayer, reflecting their identical time of birth, whereas daughter BrdU + neurons have a broader laminar distribution, reflecting diverse cells of origins (VZ and SVZ) and developmental trajectories ( by electroporating BrdU-labeled plasmids 14 . By contrast, FT + cells labeled at the same time were visible as a synchronized cohort, with strongly labeled FT + cells at the SVZ/IZ border and more weakly labeled FT + cells (most probably recycling progenitors) in the VZ (Fig. 3c ).
Potential further applications of FlashTag
Although within the CNS, FT has been best characterized in the neocortex of the mouse between embryonic days 10.5-17.5 (E10.5 and E17.5), it can be applied to other brain regions and, in principle, can be used to birth-date and isolate any type of neuron that is born in contact with the ventricular space (or, potentially, any other cavity with fluid turnover, such as the eye) throughout the brain and spinal cord, including in adult neurogenesis, across species and in organoid preparations 17 . In addition, FT can be used to label cells that migrate long distances from their place of birth, such as neurons of the olfactory bulb (Fig. 4) , and CFSE has been used to tag cells migrating through a given region by intraparenchymal injection 18 . The main limitation of this broad potential is the need to calibrate the half-life of FT in each condition, as temporal precision in tagging will depend on factors such as cerebrospinal fluid dynamics, permeability of the ventricular wall and VZ progenitor division kinetics. Finally, as fluorescence distributes into the cytoplasm, FT allows visualization of the morphology of labeled cells, including, in some instances, projections (e.g., axons but also basal processes in radial glia).
Interestingly, by allowing the temporally precise labeling of sequentially born neuronal populations, FT could be used as a template to establish correspondences between equivalent populations of cells across distantly related species (e.g., mammals versus sauropsids) without the need for potentially arbitrary molecular markers. By allowing the isolation of isochronic neurons at precise sequential developmental stages, FT can also be used to directly characterize the transcriptional progression of cell populations over time and to validate or refine bioinformatics pseudotime alignment approaches 7, 19 . Finally, FT can be combined with other techniques, such as in utero electroporation, to specifically assess the effect of gene manipulation on a temporally restricted cohort of cells, as we have done 7 . Of note, if combining FT with in utero electroporation, in the neocortex, on E14.5, FT should be performed 4-6 h after electroporation to ensure double labeling. This interval corresponds to the time that electroporated cells require to reach the ventricular border (i.e., the S-to-M duration) and thus to be able to be labeled by FT. Importantly, the electroporation-to-FT delay should be calibrated for each structure and developmental stage to allow for optimal co-labeling.
Although we have used FT to label cells only within the CNS, FT could potentially be used to label newborn cells in other systems as well, as interkinetic migration is found in many organs and species during development [20] [21] [22] [23] . In principle, any structure in which progenitor cells divide in touch with a fluid-filled cavity and then migrate away could be targeted for FT labeling. This could include the developing eye, gut, vasculature and even organoid preparations. If tested in these structures, the injection volume must be calibrated carefully, and fluid turnover in the cavity, tissue permeability and cell-cycle kinetics of progenitor cells must be considered, as these parameters will determine the effectiveness of the labeling procedure.
Limitations of FlashTag
• In the neocortex, the FT signal is retained up until the third postnatal week. Over time, labeling becomes less bright, most probably because of turnover/degradation of the proteins to which CFSE is covalently bound. However, when using CFSE, it is possible to enhance the signal through immunohistochemistry, using an anti-fluorescein (FITC) antibody (see the Procedure and Fig. 5 ). When examining brains at early time points after FT labeling (e.g., 1 h), weak fluorescence can be observed in cells that were labeled by diffusion of CFSE into the VZ. A maximum-intensity threshold can be applied to increase the signalto-noise ratio and to eliminate signal observed due to nonmitotic labeling (Fig. 5a ).
• Care should be taken when analyzing cells close to the injection site, as contamination with unspecific labeling can occur along the needle tract.
• When examining labeled cells in the neocortex at P7, the top 10% brightest cells essentially correspond to cells that were directly born from the VZ at the time of FT labeling (i.e., only 10% of those are colabeled by chronic BrdU perfusion; see Fig. 2 ). As mentioned above, it is necessary to confirm this threshold in each examined brain structure and developmental stage by combining FT with chronic BrdU or EdU perfusion, which, in our experience, is most reliably performed using an intraperitoneally implanted Alzet pump (see refs 7, 24 ). In addition, it should be noted that even when using chronic BrdU labeling, false positives are possible in the FT + BrdU + cells (i.e., these cells might wrongly be assumed to be born indirectly from the labeled progenitor, yet be directly born from a recycling progenitor at a later developmental stage).
• The FT signal bleaches very rapidly, and thus the use of a spinning-disk confocal microscope is required when performing long live-imaging experiments of FT-labeled cells. Use of antifade imaging reagents may increase the stability of the signal. In addition, note that when using FT to isolate cells for cell culture, the signal disappears substantially faster than that of in vivo culture.
• FT labels any type of cell that comes into direct contact with the cerebrospinal fluid during the time window of labeling, and labeling cannot be restricted to a specific population of cells other than by means of location. However, FT can be combined with reporter plasmids or reporter mouse lines to follow a genetically defined population of cells over time.
Experimental design
Injection parameters should be determined on a case-by-case basis, taking into account the location of the structure of interest as well as the age of the injected embryo. The initial signal intensity depends on the injection site (i.e., the signal is strongest in cells closest to the injection site) and volume, such that these two parameters should be calibrated to achieve optimal labeling in the cells of interest. For example, although bilateral cortical labeling is achieved upon injection into the lateral ventricle, the signal is strongest on the side ipsilateral to the injection site, such that the two sides cannot be directly compared with one another without calibration. In this particular case, injection into the third ventricle can be used to achieve a more homogeneous labeling. In addition, the route of injection should not be directly through the anatomical region of interest, as cells along the pipette track will be labeled. If leakage of FT is observed during injection, e.g., onto the pia, or if the injection is performed incorrectly and the injection site is located in the parenchyma instead of the ventricular cavities, brains should be excluded from analysis.
Materials Biological materials
• Mice. We have performed FT labeling in CD1 mice (Charles River Laboratories, strain code IGS); other strains can be used, but adjustments in injection volume may be needed. ! CAUTION Experiments using live rodents must conform to all relevant governmental and institutional regulations. Permission from the Geneva Cantonal Authorities, Switzerland, was obtained to perform the experiments on animals. (Optional) Magnesium sulfate Dissolve 10 mg of magnesium sulfate (Mg 2 SO 4 ) in 5 ml of sterile water (final concentration is 2 mg/ml) and sterilize, using a filter. Aliquots can be stored at 4°C; monitor for contamination if stored for several months.
Reagents

Wash buffer (PBST)
Prepare 0.01% (vol/vol) Triton X-100 in 1× PBS. The buffer can be stored at 4°C or room temperature (RT: 20-25°C) for several months; monitor for contamination if stored for several months.
Hoechst stock
Prepare a 10 mg/ml stock in 1× PBS and divide into aliquots. Aliquots can be stored at 4°C for several months.
(Optional) Blocking-permeabilization buffer Prepare 5% (vol/vol) normal horse serum (NHS) with 0.3% (vol/vol) Triton X-100 in PBS. The buffer can be stored at 4°C for several months; monitor for contamination if stored for several months.
Equipment setup
Alzet pump Fill a 3-d Alzet pump with 100 μl of 16 mg/ml BrdU or 10 mg/ml EdU with the help of a syringe and the provided blunt needle. Place the pump in saline and incubate for at least 4 h or overnight at 37°C to induce release. c CRITICAL If pump induction is skipped, release will be not stable over the first 4 h. If chronic perfusion is required for more than 72 h, a new pump must be added 72 h after perfusion start to replace the previous one. In our experience, adding a new 3-d pump after 72 h is preferable to using a 7-d pump to ensure stable release of BrdU over time. Use of a 7-d pump can result in very weak labeling after 3 d, most probably because of degradation of BrdU over time.
Pipette preparation
Pull a glass capillary with the glass micropipette puller and cut the tip of each side to obtain an external diameter of 40-80 µm. Using a microelectrode beveler, bevel each pulled 15 a sharp tip (Fig. 6a) . CRITICAL See ref. 25 for a movie relating to in utero electroporation, in which the initial steps are similar to the ones described here. 3 Place the mouse in the anesthesia induction box and anesthetize, using appropriate isoflurane and oxygen levels. ! CAUTION Experiments using live rodents must conform to all relevant governmental and institutional regulations. Permission from the Geneva Cantonal Authorities, Switzerland was obtained to perform the experiments on animals. 4 Place the mouse on its back on a heated surgery platform, with the snout inside the inhalation tube (Fig. 6b) . c CRITICAL STEP The surgery should be finished within 20-30 min of this point. 5 Apply eye gel to the eyes of the mouse to prevent them from drying out during the surgery. 6 Fix the hind paws on the surgery heating pad, using adhesive medical tape. 7 Inject analgesic i.p. (100 µl of 0.03 mg/ml buprenorphinum). 8 Disinfect the abdomen using a tissue soaked with chlorhexidine. 9 Make a midline incision of~1-2 cm to expose the uterine horns. Place a sterile cotton pad on the lower part of the abdomen and moisturize with warm saline. 10 With the help of a cotton swab, carefully remove the uterine horns from the abdominal cavity and place them on the cotton pad. c CRITICAL STEP Handle the uterine horns carefully and apply only minimal pressure. c CRITICAL STEP Keep the uterine horns moist throughout the surgery, using lukewarm saline. 11 (Optional) If the uterine horns are contracted, relax them by applying two to three drops of 2 mg/ml Mg 2 SO 4 solution. Instantly rinse the solution off with warm saline. c CRITICAL STEP Use of Mg 2 SO 4 is recommended only for embryos younger than E14.5. c CRITICAL STEP If Mg 2 SO 4 is not instantly washed away with saline, it can cause damage to the uterine horns and result in abortions. c CRITICAL STEP High concentration and volume of Mg 2 SO 4 can result in abortions. ? TROUBLESHOOTING 12 Inject 0.5 µl of FT into the ventricle, using a nanoinjector (Fig. 6c) . Injection can be performed in the lateral or the third ventricle, depending on the structure of interest (for strong labeling in the Fig. 6 | Pipette preparation and surgical procedure. a, Pulled glass microcapillaries are beveled using a micropipette beveler to achieve a sharp tip with an outer diameter between 40 and 80 μm. b, The anesthetized dam is placed on the surgical setup, and the uterine horns are carefully pulled out and placed on a sterile cotton pad. Embryos are visualized using illumination, and FT is injected into the ventricle is performed, resulting in the labeling of cells at the border of the ventricle. c, To perform intraventricular injection, embryos are held between the thumb and forefinger, and venous sinuses are used to identify the position of the ventricle (white arrowhead). After injection into the ventricle, Fast Green is visible in the injected ventricle (green arrowhead), and lower intensity is seen in the rest of the ventricular system (gray arrowhead). Scale bar, 2 mm. For all experiments involving animals, appropriate institutional regulatory board permission was obtained. Illustration in b adapted from ref. 26 .
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cortex, embryos older than E14.5 should be injected in the lateral ventricle). If injection is performed correctly, Fast Green will be visible in the ventricle. c CRITICAL STEP Excessive volume or speed of injection can result in hydrocephaly or death of the embryo. c CRITICAL STEP Pierce the uterine horn slowly and gently to avoid damage to the uterine wall, as this can lead to abortion. c CRITICAL STEP Use of mouth-pipetting techniques will probably result in variable volumes of injection, and comparison of FT intensities across embryos will thus be unreliable. ? TROUBLESHOOTING 13 Place the uterine horns carefully back into the abdominal cavity. 14 Fill the abdominal cavity with lukewarm saline. 15 Carefully place the Alzet pump into the abdominal cavity for chronic BrdU or EdU administration. 16 Close the peritoneal wall and then the skin, using an absorbable suturing thread. Alternatively, metallic clips can be used. 17 Inject analgesic i.p. (100 µl of 0.03 mg/ml buprenorphinum) and return the mouse to its cage.
? TROUBLESHOOTING 18 Place the cage on a heating pad. The mouse should recover within a few minutes. and dissect the FT + brains (Fig. 7a,b) . c CRITICAL STEP Keep the brains in HBSS on ice whenever possible to minimize cell death. (iii) Embed the brains in 42°C agarose, using plastic molds placed on ice. (iv) Once the agarose solidifies, carefully remove the agar block from plastic mold. Using a blade, remove the excess agarose and cut small blocks, leaving no more than 3 mm of agarose around the brain. (v) Glue the agarose blocks containing the tissue to the vibrating microtome support and cut 300-to 600-µM-thick coronal sections at low speed and vibration. Collect the slices in a Petri dish with ice-cold HBSS, using an embryo spoon. (vi) With the help of a stereomicroscope, dissect the regions of interest, using microknives, and use a plastic pipette to transfer the dissected parts to a 1.5-ml microcentrifuge tube placed on ice. c CRITICAL STEP When acquiring the images, maintain the entire dynamic range (allowing only a few over-and undersaturated pixels). (xiii) Adjust the contrast during image postprocessing to highlight the cells in the top 50% in intensity (i.e., the brightest cells) to identify the high FT + population (i.e., the cells that were labeled by mitotic uptake of FT and that did not undergo subsequent cell division).
Troubleshooting
Troubleshooting advice can be found in Table 2 .
Timing
Steps 1 and 2, preparation for surgery: 10 min Step 24A, FACS sorting of FT + population from FT-injected embryos: 120 min
Step 24B(i,ii), dissection and fixation of brains: 1 d
Step 24B(iii-vi), vibratome sectioning and incubation with primary antibody: 1 d
Step 24B(vii-xi), incubation with secondary antibody and mounting of sections: 4 h
Step 24B(xii,xiii), imaging and thresholding for high FT + population: 4 h
Anticipated results
Across the CNS, mitosis of progenitors located in the VZ (i.e., apical progenitors) occurs as the somata of these cells are in contact with the ventricular space. FT takes advantage of this characteristic anatomical location of mitotic apical progenitors. This topographical specificity is in contrast to BrdU labeling, in which all S-phase cells are labeled independently of their location (VZ, SVZ and IZ; Fig. 3a) . FT-labeled cells can be easily followed from birth until at least 3 weeks postnatally, even after migration of cells over long distances. Examples of typical FT labeling are presented in Fig.  3b (neocortex) and Fig. 4b (olfactory bulb). Labeled cells can be isolated with FACS for various applications, including single-cell RNA sequencing, or live tissue can be collected for live imaging or electrophysiology. A maximum-intensity threshold can be used to strongly enrich for cells that were directly born from the VZ at the time of FT labeling, both when isolating cells using FACS, in which gating is performed to collect the brightest 5-10% of cells ( Fig. 7c and Supplementary Fig. 1 ), as well as when analyzing labeled cells with histology (Fig. 5) . 
Reporting Summary
Further information on experimental design is available in the Nature Research Reporting Summary linked to this article. 
